Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. by Os, M.A. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a postprint version which may differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/97255
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Preventing preterm birth with progesterone: costs and effects of screening low
risk women with a singleton pregnancy for short cervical length, the Triple P
study
BMC Pregnancy and Childbirth 2011, 11:77 doi:10.1186/1471-2393-11-77
Melanie A van Os (m.vanos@vumc.nl)
Jeanine A van der Ven (a.j.vanderven@amc.uva.nl)
Emily C Kleinrouweler (c.e.kleinrouweler@amc.uva.nl)
Eva Pajkrt (e.pajkrt@amc.uva.nl)
Esteriek de Miranda (e.demiranda@amc.uva.nl)
Aleid van Wassenaer (a.vanwassenaer@amc.uva.nl)
Martina Porath (m.porath@mmc.nl)
Patrick M Bossuyt (p.m.bossuyt@amc.uva.nl)
Kitty WM Bloemenkamp (k.w.m.bloemenkamp@lumc.nl)
Christine Willekes (c.willekes@mumc.nl)
Mallory Woiski (m.woiski@obgyn.umcn.nl)
Martijn A Oudijk (m.a.oudijk-3@umcutrecht.nl)
Katia M Bilardo (c.m.bilardo@og.umcg.nl)
Marko J Sikkema (j.sikkema@zgt.nl)
Johannes J Duvekot (j.j.duvekot@erasmusmc.nl)
Diederik Veersema (diederik.veersema@diagnostiekvooru.nl)
Jacqueline Laudy (jla1@star-mdc.nl)
Petra Kuiper (petranadine@live.nl)
Christianne JM de Groot (cjm.degroot@vumc.nl)
Ben Willem J Mol (b.w.mol@amc.uva.nl)
Monique C Haak (m.c.haak@lumc.nl)
ISSN 1471-2393
Article type Study protocol
Submission date 8 August 2011
Acceptance date 24 October 2011
Publication date 24 October 2011
Article URL http://www.biomedcentral.com/1471-2393/11/77
BMC Pregnancy and Childbirth
© 2011 van Os et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Like all articles in BMC journals, this peer-reviewed article was published immediately upon
acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright
notice below).
Articles in BMC journals are listed in PubMed and archived at PubMed Central.
For information about publishing your research in BMC journals or any BioMed Central journal, go to
http://www.biomedcentral.com/info/authors/
BMC Pregnancy and Childbirth
© 2011 van Os et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 - 1 - 
Preventing preterm birth with progesterone: costs and 
effects of screening low risk women with a singleton 
pregnancy for short cervical length, the Triple P study 
 
Melanie A van Os1§,  Jeanine A van der Ven2*, Emily C Kleinrouweler2*, Eva 
Pajkrt2* , Esteriek de Miranda2*, Aleid van Wassenaer3*, Martina Porath4*, Patrick M 
Bossuyt5*, Kitty WM Bloemenkamp6*, Christine Willekes7*, Mallory Woiski8*, 
Martijn A Oudijk9*, Katia M Bilardo10*, Marko J Sikkema11*, Johannes J 
Duvekot12*, Diederik Veersema13*, Jacqueline Laudy14*, Petra Kuiper15*, Christianne 
JM de Groot1*, Ben Willem J. Mol2*, Monique C Haak6* 
 
1 Department of Obstetrics and Gynaecology, VU Medical Centre, Amsterdam, the 
Netherlands,  
2 Department of Obstetrics and Gynaecology, Academic Medical Centre Amsterdam, 
the Netherlands,  
3
 Department of Neonatology, Emma Children’s Hospital Academic Medical Centre, 
Amsterdam, the Netherlands,  
4  Department of Obstetrics and Gynaecology, Máxima Medisch Centrum, Veldhoven, 
the Netherlands,  
5 Department of Clinical Epidemiology, Academic Medical Centre, Amsterdam, the 
Netherlands,  
6 Department of Obstetrics and Gynaecology, Leiden University Medical Centre, 
Leiden, the Netherlands,  
7 Department of Obstetrics and Gynaecology, Academic Hospital, Maastricht, 
Maastricht, the Netherlands,  
 - 2 - 
8 Department of Obstetrics and Gynaecology, Radboud University, Nijmegen, the 
Netherlands,  
9 Department of Obstetrics and Gynaecology, University Medical Centre, Utrecht, the 
Netherlands,  
10 Department of Obstetrics and Gynaecology, University Medical Centre, Groningen, 
the Netherlands,  
11
 Department of Obstetrics and Gynaecology, ZHT, Almelo, the Netherlands  
12
 Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, 
the Netherlands,  
13 Diagnostiek voor u diagnostisch centrum, Eindhoven, the Netherlands,  
14 Star Medisch Diagnostisch Centrum, Rotterdam, the Netherlands,  
15
 Ultrasound centre FARA, Ede, the Netherlands.  
 
 
*These authors contributed equally to this work 
§Corresponding author 
 
Email addresses: 
MAO:m.vanos@vumc.nl 
JAV: a.j.vanderven@amc.uva.nl  
ECK: c.e.kleinrouweler@amc.uva.nl 
EP: e.pajkrt@amc.uva.nl  
EM: e.demiranda@amc.uva.nl  
AW: a.vanwassenaer@amc.uva.nl  
MP : m.porath@mmc.nl  
 - 3 - 
PMB : p.m.bossuyt@amc.uva.nl  
KWMB : k.w.m.bloemenkamp@lumc.nl  
CW : c.willekes@mumc.nl   
MW : m.woiski@obgyn.umcn.nl  
MAO :  m.a.oudijk-3@umcutrect.nl 
KMB : c.m.bilardo@og.umcg.nl   
MJS : j.sikkema@zgt.nl  
JJD : j.j.duvekot@erasmusmc.nl 
DV : diederik.veersema@diagnostiekvooru.nl  
JL : jla1@star-mdc.nl  
PK : petranadine@live.nl  
CJMG : cjm.degroot@vumc.nl 
BWJM : b.w.mol@amc.uva.nl 
MCH : m.c.haak@lumc.nl 
 - 4 - 
Abstract  
Background 
Women with a short cervical length in mid-trimester pregnancy have a higher risk of 
preterm birth and therefore a higher rate of neonatal mortality and morbidity. 
Progesterone can potentially decrease the number of preterm births and lower 
neonatal mortality and morbidity. Previous studies showed good results of 
progesterone in women with either a history of preterm birth or a short cervix. 
However, it is unknown whether screening for a short cervix and subsequent 
treatment in mid trimester pregnancy is effective in low risk women.  
 
Methods/Design 
We plan a combined screen and treat study among women with a singleton pregnancy 
without a previous preterm birth. In these women, we will measure cervical length at 
the standard anomaly scan performed between 18 and 22 weeks. Women with 
cervical length ≤ 30mm at two independent measurements will be randomly allocated 
to receive either vaginal progesterone tablets or placebo between 22 and 34 weeks. 
The primary outcome of this trial is adverse neonatal condition, defined as a 
composite outcome of neonatal mortality and severe morbidity. Secondary outcomes 
are  time to delivery, preterm birth rate before 32, 34 and 37 weeks, days of admission 
in neonatal intensive care unit, maternal morbidity, maternal admission days for 
preterm labour and costs. We will assess growth, physical condition and 
neurodevelopmental outcome of the children at two years of age.  
 
Discussion 
This study will provide evidence for the usefulness and cost-effectiveness of 
screening for short cervical length at the 18-22 weeks and subsequent progesterone 
treatment among low risk women. 
 
Trial registration Netherlands Trial Register: NTR207 
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Background  
Spontaneous preterm delivery is the single most important cause of perinatal mortality 
in the Western world [1]. It is known that cervical length measurement at 20 to 24 
weeks gestation can identify women at increased risk for preterm delivery [2,3]. 
However, an effective treatment was not available until recently.  
A breakthrough in the management of women at increased risk is the use of 
progesterone. Two randomized clinical trials demonstrated a reduction in preterm 
birth of 50% in women with a previous preterm birth [4,5]. The number of women 
who delivered prior to 32 weeks in both studies decreased from 20% to 10%. The 
effectiveness of progesterone was also addressed in a recent meta-analysis [6]. 
Relative to women allocated to placebo, those who received progestational agents 
(17[alpha]-hydroxyprogesterone caproate and other forms of progesterone) had lower 
rates of preterm delivery (26% versus 36%), corresponding to a number needed to 
treat to prevent one premature delivery of 10. In addition, women who had received 
progestational agents had lower rates of perinatal mortality (14.8% versus 17.1%). 
 
The problem with the use of progesterone at present is that, based on current 
evidence, it can only be applied to women with a history of preterm birth. However, 
the large majority of spontaneous preterm delivery occurs in nulliparous women, and 
progesterone has not been assessed in those women [7]. On the other hand, prediction 
of preterm birth in nulliparous women has been studied widely. Fetal fibronectin, 
cervical length, upper genital tract infection, and bacterial vaginosis are predictors of 
preterm birth and in various combinations, proved to be stronger predictors, 
depending on race and gestational age. At 24 weeks, cervical length below 25mm was 
the best predictor of spontaneous preterm birth at all gestational ages. Of the risk 
factors evaluated at 28 and 30 weeks, fetal fibronectin was the only significant 
predictor of spontaneous preterm birth < 32 weeks [8]. 
  
In a European cohort of 47.123 women, the cervix was 15mm or less in 470. The 
proportion of preterm delivery in this group was almost 25%. In a randomised clinical 
trial attached to this study, the insertion of a Shirodkar suture in women with a short 
cervix did not substantially reduce the risk of early preterm delivery [9]. 
In view of the studies mentioned above, two conclusions can be drawn. First, 
progesterone is an effective treatment for women who are at increased risk for 
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preterm birth due to a previous spontaneous preterm delivery. Second, routine 
sonographic measurement of cervical length at 22-24 weeks identifies a group of 
nulliparous women at increased risk of early preterm birth.  
 
These two issues generate the hypothesis that the use of progesterone in women with 
a short cervical length can reduce the preterm delivery rate. In August 2007, the first 
randomised study on the effectiveness of progesterone in women with a singleton 
pregnancy and a short cervical length without a history of spontaneous preterm birth 
was published [4]. Spontaneous delivery before 34 weeks of gestation was less 
frequent in the progesterone group than in the placebo group (19% vs. 34% relative 
risk, 0.56). Progesterone was associated with a non-significant reduction in neonatal 
morbidity (8.1% vs. 13.8%; relative risk, 0.59, P = 0.17). There were no serious 
adverse events associated with the use of progesterone. The authors concluded that in 
women with a short cervix, treatment with progesterone reduces the rate of 
spontaneous early preterm delivery. However, as a significant effect on neonatal 
outcome was lacking, additional data are needed. We propose a national cohort study 
in which mid trimester cervical length is measured in 15.000 women, with subsequent 
randomisation of women with a decreased cervical length. The costs and effects of 
screening and treatment will be assessed, taking into account different cut-off values 
of short cervical length.  
 
Methods/Design 
The study is set in the Dutch Obstetric Consortium a collaboration of obstetric 
practices in the Netherlands. Approximately 200 clinics, including university 
hospitals, teaching hospitals, non-teaching hospitals, ultrasound centres and 
midwifery practices will participate in this trial. 
To conduct this trial we got approval from the Medical Ethical Committee, Academic 
Medical Centre, Amsterdam the Netherlands (MEC AMC 08-374 and 08-328). The 
study will be a cohort study with a randomised clinical trial embedded. We will 
screen a large cohort of women with low risk singleton pregnancies at 18-22 weeks 
gestation. Women with a short cervix will then be randomly allocated to receive either 
vaginal progesterone or placebo until 34 weeks. 
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Procedures, recruitment, randomisation and collection of baseline data 
In the Triple P screening study, we will offer low risk women with a singleton 
pregnancy the possibility to screen for a short cervix. Women < 18 years of age, 
women with a previous preterm birth < 34 weeks or symptoms of threatened preterm 
labour (uterine contractions, ruptured membranes), fetal congenital malformations and 
cervical or abdominal cerclage in situ will be excluded.  
 
The cervical length is measured in addition to the standard anomaly scan at 18-22 
weeks gestation, which all pregnant women are offered in the Netherlands. At the end 
of the standard anomaly scan, the measurement will be performed using a vaginal 
probe. The bladder of the participant needs to be empty. The measurement takes 
approximately three minutes and the shortest measurement is used. All participating 
sonographers will be asked to complete an e-learning module, specifically designed to 
learn the cervical length measurement technique. Subsequently, prior to participation 
in the study, each sonographer will be asked to obtain pictures of five measurements, 
which will be judged by the project team.  
 
The cut off level for a short cervical length is ≤ 30mm. Initially the cut of level was 
set at ≤ 25mm. However, after we had screened 340 women, only 9 patients had a 
cervical length ≤ 25mm at first measurement; a far lower rate than expected. Based on 
these findings the cut of level was altered to ≤ 30 mm, which corresponded to other 
recruiting trials. 
 
When a cervical length ≤ 30 mm is measured, a second assessment is offered within 
two weeks. 
This second measurement takes place in the same hospital. When the first 
measurement is done in an ultrasound centre, the second measurement takes place in 
the nearest hospital and is performed by a trained sonographer. 
 
If at the second assessment the cervix remains ≤ 30mm, women will be invited to 
participate in the randomised clinical trial. Women who are eligible for the study but 
do not give informed consent, are registered and data on their pregnancy outcome will 
be collected. Progesterone will not be offered to these women.  
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All eligible women with a singleton pregnancy and cervical length ≤ 30mm will be 
informed shortly about the clinical trial by the supervising gynaecologist or midwife. 
Subsequently, a trained research nurse will inform the patient in detail. The patient 
will also receive written information about the study from the research nurse. 
Following the study information, the woman is given a minimal of five days time to 
consider participation in the clinical trial. In case of participation, informed consent is 
obtained for the treat study.    
 
Once informed consent has been given, and patient data have been entered in a web 
based database, computerized randomisation will take place. 
 
Intervention 
Each study participant will be given a blister pack labelled “Progesterone Study,”  
that will contain either 200-mg capsules of micronized progesterone (Utrogestan, 
Besins International Belgium) or identical-appearing capsules of placebo (Medicaps). 
Progesterone use did not show side effects in other studies, there was no difference 
observed between exposed and non exposed infants. [10,11,12]. 
Study medication will be taken between 22 weeks and 34 weeks gestational age. The 
capsules will be self-administered vaginally by patients on a daily basis. The label 
codes indicating progesterone or placebo are only known in the central pharmacy. 
These data will be disclosed to the central office only after data on primary outcome 
have been collected. Researchers involved in the follow up program of the offspring 
of women participating in this study will remain blinded for a longer period. For 
emergency cases, a closed envelope with the label codes is available at the study 
centre. For purpose of the interim analysis the label codes will become available to 
the epidemiologist involved in the study as A and B. Baseline demographic, past 
obstetric and medical history will be recorded of all women who participate in the 
randomised study. 
 
Outcome measures 
The primary outcome measure is composite poor neonatal outcome (death or severe 
morbidity). This composite morbidity rate contains the following variables: severe 
Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), 
Periventricular Leucomalacia > grade 1, Intracerebral Haemorrhage > grade II, 
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Necrotizing Enterocolitis (NEC) > stage 1, proven sepsis and death before discharge 
from the nursery. The primary outcome measure will be recorded 10 weeks after the 
expected term date.  
 
Secondary outcome are time to delivery, preterm birth rate before 32, 34 and 37 
weeks, days of admission in neonatal intensive care unit, maternal morbidity, 
maternal admission days for preterm labour and costs. Moreover, growth, physical 
condition including close examination of the genital tract, and neuro-developmental 
outcome of the child at 24 months (corrected) age will be assessed. 
Next to secondary clinical outcome, the cost-effectiveness of screening for short 
cervical length (as done in Triple P screening), and subsequent treatment in case of a 
short cervix, will be assessed for several cut-off levels of cervical length. 
 
Follow up of women and infants 
Follow up will be performed in all children. Questionnaires regarding child 
development will be sent to all participating families at the corrected child age of 24 
months. Child outcomes to be measured are; length, weight and head circumference, 
medical history and medical consumption, physical examination with extra attention 
for the genital tract, neurological examination (including gross motor functional 
classification system for children with cerebral paresis). assessment of the cognitive 
and motor development, using the Bayley Scales of Infant Development, version III. 
Child Behavioural Checklist, will be filled out by the parents to assess behavioural 
outcome. Ages and stages questionnaire will be filled out by all parents 
 
Statistical issues 
Sample size calculation 
We anticipated an adverse neonatal outcome in 14% of the pregnancies in which the 
cervical length is < 15mm, and in 3% of the pregnancies with a cervical length 
between 15 mm and 30mm. As we assumed that 1.7% of the pregnancies would show 
a cervical length <15 mm, and 8.3% of the pregnancies a cervical length between 15 
and 30mm, the probability of bad neonatal outcome without intervention with 
progesterone in women with a cervix shorter or equal to 30mm will be 5.0%. This 
percentage was expected to be reduced to 2.5% after use of progesterone. Assuming 
this decrease of the incidence of adverse neonatal outcome from 5% to 2.5%, using a 
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two sided test with an alpha of 0.05 and a beta of 0.8, 1,920 women (960 per arm) 
were needed in this study. As we expected that 10% of the women would have a 
cervix ≤ 30mm, and with the assumption that 50% of the eligible women would 
participate, we need to screen almost 40,000 women in the Triple P screening study. 
However since the start of the study, 3.000 women were screened resulting in only 70 
patients with a cervical length ≤30mm at the first measurement; a far lower rate of 
short cervix  than we expected. Based on these findings, the feasibility of recruitment, 
the available budget and the example of similar international trials we have adjusted 
our protocol and plan to screen 15.000 women. Based on the current data, we 
hypothesize that we will be able to randomize 100 women. We aim to combine the 
trial data with that of other ongoing studies on the subject in an individual patient data 
meta analysis. (13).  
 
Data analysis 
The results of the randomised clinical trial will be analysed according to the intention 
to treat principle. The effectiveness of progesterone versus placebo will be assessed 
by calculating relative risks and 95% confidence intervals. Time to delivery will be 
compared using Kaplan-Meier curves and log-rank tests. We will evaluate whether 
there is an interaction between the treatment effect and cervical length, and between 
treatment effect and ethnicity. 
 
Economic evaluation 
General considerations 
The economic analysis will be performed from the societal perspective. Both costs 
and outcomes will be discounted with a discount rate of 5%. The economic analysis 
of the trial itself is not of interest. If progesterone is found to decrease the probability 
of preterm delivery, then the savings due to decreased prematurity will always 
outweigh the costs of progesterone, which are negligible. The true economic question 
to be answered when the trial shows a beneficial effect is whether the costs of 
screening (number needed to screen to detect one woman with a short cervix) 
outweigh the cost reduction and health benefits from treatment with progesterone.  
  
 
 
 - 11 - 
Cost analysis 
The study design will enable us to compare the costs and effects of the following 
strategies:  
 
I. no screening for cervical length  
II. screening for cervical length, and treatment of women with a short cervical length  
 
For each of these strategies, we will calculate the costs as well as the effects in terms 
of poor neonatal outcome (mortality and severe morbidity, see above). In the cost-
effectiveness analysis, we will then calculate the costs per prevented case of bad 
neonatal outcome.  
For strategy II, we will assess the screening strategy using different cut-off levels. We 
anticipate a stronger treatment effect in the group with a very short cervix, i.e. < 
15mm, whereas the treatment effect is likely to be less strong in the women with a 
cervix between 15 mm and 30 mm (number need to treat). On the other hand, the 
number of women with a short cervix will be smaller when a cut-off value of 15mm is 
used than when the group with a cervix between 15 and 30mm is considered to be 
abnormal (number needed to screen). Thus, the cost-effectiveness analysis will assess 
the balance between number needed to treat and number needed to screen.  
 
For the cost analysis, the process of care is divided into three cost stages (antenatal 
stage, delivery/childbirth, postnatal stage) and three cost categories (direct medical 
costs [all costs in the health care sector], direct non-medical costs [costs outside the 
health care sector that are affected by health status or health care] and indirect costs of 
the pregnant woman and her partner [costs of sick leave]). Volumes of health care 
resource use are measured prospectively alongside the clinical study in all 
participating centres as part of the case report form. 
  
Cost volumes in the antenatal stage consist of direct medical costs (e.g. prenatal 
checkups, costs of screening, admission due to threatened preterm birth, transport of 
patients to perinatal centres, and maternal monitoring [various lab tests; hospital 
care]).  Costs during childbirth are dominated by the course of childbirth and type of 
delivery. Cost volumes in the postnatal stage consist of maternal care (hospitalisation 
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etc.) and neonatal care (admission to neonatal intensive care/neonatology ward, 
outpatient visits) and primary care.  
 
Health resource use outside the hospital is recorded by questionnaires. Direct medical 
volumes outside the hospital and direct non-medical volumes are valued using 
national reference prices. Indirect costs are quantified but remain unvalued. Study-
specific costs are excluded from analysis.  
 
Discussion  
Preterm birth is still a huge problem, with high mortality and morbidity rates. 
Progesterone is a safe and potentially effective treatment for prevention of preterm 
birth. Some studies have already proven the use of progesterone in high risk 
populations, showing that the number of preterm births can be reduced. 
Unfortunately there is no evidence that progesterone use decreases neonatal morbidity 
and mortality. More research has to be done on the possible effects of progesterone on 
the neonatal morbidity and mortality rates. 
Simultaneously with the Triple P trial, a number of other study groups in different 
countries have set up trials to evaluate the effect of progesterone on low risk 
pregnancy’s to prevent preterm birth.  
Recently one of those study’s showed a reduction of preterm birth rate with the use of 
progesterone [13]. 
If the outcome and data of these studies are pooled a more conclusive statement can 
be made on this matter. 
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